BODi Expands GLP-1 Support and Longevity-Driven Fitness with 10 Minute BODi Workouts April 21, 2026 Built for busy people, new targeted microdose fitness programs help preserve and build muscle, support metabolic health, and avoid disease with consistent fitness in just 10 minutes BODi (NASDAQ: BODI) today announced the expansion of its 10 Minute BODi catalogue with three new digital programs, accelerating its push to make consistent fitness more achievable for more people
PMID 16801493
It's available under three FDA-approved brand names: Ozempic for type 2 diabetes: a weekly injectable Wegovy for weight loss: a weekly injectable Rybelsus for type 2 diabetes: an oral tablet Semaglutide is a synthetic version of GLP-1, a natural hormone that regulates appetite and blood glucose
You can run a full schedule and still be leaving thousands on the table each month
The forward-looking statements contained in this communication are made only as of March 18, 2026
Guerra V, Ologun GO, Haydu LE, Keung E, Burton EM, Tawbi H, Wierda WG, Davies MA , Wargo JA, Ferrajoli A
